ABBV
AbbVie Inc.
Quarterly revenue, EPS, free cash flow, valuation, and Rule of 40 scores for AbbVie Inc..
Coverage
AbbVie Q2 2026: Skyrizi and Rinvoq Keep Compounding — Stock Falls on a Narrow EPS Miss
AbbVie beat revenue estimates as Skyrizi and Rinvoq grew over 24% each, but adjusted EPS missed by 6 cents and full-year guidance came down, sending shares down nearly 5%. We break down the immunology growth story against the near-term guidance drag.
AbbVie Posts Double Beat for Q4
Q4 EPS $2.71 vs $2.65 est, revenue $16.62B vs $16.42B est; FY26 EPS guidance $14.37-$14.57 vs $14.24 est, signaling robust earnings growth.
AbbVie All In on Obesity
AbbVie signals heavy obesity focus without explicit statement; expected to compete with Novo Nordisk, Merck, Bristol-Myers Squibb, emphasizing efficacy over oral vs. subcutaneous.
AbbVie at JPM is All In on Obesity
AbbVie expresses enthusiasm for phase 1-2 obesity assets; anticipates big showdown with competitors like Novo Nordisk, Merck, and Lilly in weeks, not months.
Biopharma Sentiment Just Snapped Higher
Biopharma sentiment surged with BPSI index jumping 78 to 90; aligns with public market price action and deal flow, expecting continued M&A and IPO activity into summer.
Latest: $16.99B (2026Q2)
| Period | Value |
|---|---|
| 2020Q3 | $12.90B |
| 2020Q4 | $13.86B |
| 2021Q1 | $13.01B |
| 2021Q2 | $13.96B |
| 2021Q3 | $14.34B |
| 2021Q4 | $14.89B |
| 2022Q1 | $13.54B |
| 2022Q2 | $14.58B |
| 2022Q3 | $14.81B |
| 2022Q4 | $15.12B |
| 2023Q1 | $12.22B |
| 2023Q2 | $13.87B |
| 2023Q3 | $13.93B |
| 2023Q4 | $14.30B |
| 2024Q1 | $12.31B |
| 2024Q2 | $14.46B |
| 2024Q3 | $14.46B |
| 2024Q4 | $15.10B |
| 2025Q1 | $13.34B |
| 2025Q2 | $15.42B |
| 2025Q3 | $15.78B |
| 2025Q4 | $16.62B |
| 2026Q1 | $15.00B |
| 2026Q2 | $16.99B |
Latest: $2.03 (2026Q2)
| Period | Value |
|---|---|
| 2020Q3 | $1.29 |
| 2020Q4 | -$0.13 |
| 2021Q1 | $1.99 |
| 2021Q2 | $0.42 |
| 2021Q3 | $1.78 |
| 2021Q4 | $2.26 |
| 2022Q1 | $2.51 |
| 2022Q2 | $0.51 |
| 2022Q3 | $2.21 |
| 2022Q4 | $1.40 |
| 2023Q1 | $0.13 |
| 2023Q2 | $1.14 |
| 2023Q3 | $1.00 |
| 2023Q4 | $0.45 |
| 2024Q1 | $0.77 |
| 2024Q2 | $0.77 |
| 2024Q3 | $0.88 |
| 2024Q4 | -$0.03 |
| 2025Q1 | $0.72 |
| 2025Q2 | $0.52 |
| 2025Q3 | $0.10 |
| 2025Q4 | $1.02 |
| 2026Q1 | $0.39 |
| 2026Q2 | $2.03 |
Latest: 107.1 (2026Q1)
| Period | Value |
|---|---|
| 2020Q2 | 16.6 |
| 2020Q3 | 14.9 |
| 2020Q4 | 30.6 |
| 2021Q1 | 31.6 |
| 2021Q2 | 25.4 |
| 2021Q3 | 21.7 |
| 2021Q4 | 18.0 |
| 2022Q1 | 20.1 |
| 2022Q2 | 18.9 |
| 2022Q3 | 15.8 |
| 2022Q4 | 21.7 |
| 2023Q1 | 33.8 |
| 2023Q2 | 25.1 |
| 2023Q3 | 37.4 |
| 2023Q4 | 52.5 |
| 2024Q1 | 50.4 |
| 2024Q2 | 53.9 |
| 2024Q3 | 65.2 |
| 2024Q4 | 71.0 |
| 2025Q1 | 86.3 |
| 2025Q2 | 86.3 |
| 2025Q3 | 172.8 |
| 2025Q4 | 96.8 |
| 2026Q1 | 107.1 |
Latest: $3.11B (2026Q2)
| Period | Value |
|---|---|
| 2020Q3 | $5.61B |
| 2020Q4 | $4.58B |
| 2021Q1 | $4.69B |
| 2021Q2 | $4.70B |
| 2021Q3 | $7.72B |
| 2021Q4 | $4.89B |
| 2022Q1 | $4.75B |
| 2022Q2 | $4.86B |
| 2022Q3 | $7.42B |
| 2022Q4 | $7.21B |
| 2023Q1 | $4.02B |
| 2023Q2 | $6.14B |
| 2023Q3 | $7.36B |
| 2023Q4 | $4.55B |
| 2024Q1 | $3.85B |
| 2024Q2 | $2.03B |
| 2024Q3 | $5.20B |
| 2024Q4 | $6.76B |
| 2025Q1 | $1.40B |
| 2025Q2 | $4.88B |
| 2025Q3 | $6.64B |
| 2025Q4 | $4.89B |
| 2026Q1 | $3.56B |
| 2026Q2 | $3.11B |
Latest: $1,767,384,632.00 (2025Q3)
| Period | Value |
|---|---|
| 2018Q1 | $1,586,879,451.00 |
| 2018Q2 | $1,514,272,698.00 |
| 2018Q3 | $1,504,216,327.00 |
| 2019Q1 | $1,478,332,177.00 |
| 2019Q2 | $1,478,483,838.00 |
| 2019Q3 | $1,478,821,109.00 |
| 2020Q1 | $1,476,742,215.00 |
| 2020Q2 | $1,764,833,246.00 |
| 2020Q3 | $1,765,473,923.00 |
| 2021Q1 | $1,766,222,336.00 |
| 2021Q2 | $1,767,175,532.00 |
| 2021Q3 | $1,767,880,465.00 |
| 2022Q1 | $1,767,110,083.00 |
| 2022Q2 | $1,768,096,495.00 |
| 2022Q3 | $1,768,480,508.00 |
| 2023Q1 | $1,764,289,680.00 |
| 2023Q2 | $1,765,046,680.00 |
| 2023Q3 | $1,765,537,421.00 |
| 2024Q1 | $1,765,867,781.00 |
| 2024Q2 | $1,766,343,745.00 |
| 2024Q3 | $1,767,140,323.00 |
| 2025Q1 | $1,766,403,027.00 |
| 2025Q2 | $1,766,558,253.00 |
| 2025Q3 | $1,767,384,632.00 |
Latest: $184.69B (2026Q2)
| Period | Value |
|---|---|
| 2020Q3 | $69.48B |
| 2020Q4 | $74.06B |
| 2021Q1 | $78.75B |
| 2021Q2 | $83.44B |
| 2021Q3 | $91.16B |
| 2021Q4 | $96.05B |
| 2022Q1 | $100.80B |
| 2022Q2 | $105.66B |
| 2022Q3 | $113.08B |
| 2022Q4 | $120.30B |
| 2023Q1 | $124.32B |
| 2023Q2 | $130.46B |
| 2023Q3 | $137.81B |
| 2023Q4 | $142.36B |
| 2024Q1 | $146.21B |
| 2024Q2 | $148.24B |
| 2024Q3 | $153.44B |
| 2024Q4 | $160.19B |
| 2025Q1 | $161.59B |
| 2025Q2 | $166.48B |
| 2025Q3 | $173.12B |
| 2025Q4 | $178.01B |
| 2026Q1 | $181.57B |
| 2026Q2 | $184.69B |
Latest results
Company History
AbbVie was formed as a spin-off from Abbott Laboratories, focusing on research-based pharmaceuticals; became independent on January 1, 2013.
Acquired ImmuVen, a startup focused on biotherapeutics for cancer, infectious diseases, and autoimmune disorders.
Acquired oncology firm Pharmacyclics and its blood cancer treatment ibrutinib for $21 billion.
Acquired Allergan for $63 billion, with divestitures to gain regulatory approval, including brazikumab to AstraZeneca and Zenpep/Viokace to Nestlé.
Evaluated Kaletra (lopinavir/ritonavir) as a potential COVID-19 treatment, later found ineffective, and ceased patent enforcement in response to government pressure.
Acquired ImmunoGen for $10.1 billion to enter the ovarian cancer market with the drug Elahere.
Robert Michael replaced Richard Gonzalez as CEO, with Gonzalez becoming executive chairman.
Key Players
showing 6 of 18
Similar stocks in Healthcare
Funds we follow holding ABBV
By latest reported 13F position value. Market value at quarter-end, not cost basis.
